According to NewScientist, gene-editing treatments trials using CRISPR on humans have already begun, producing "very promising results in trials for cancers."
In fact, CRISPR works so well that the first human trial involving the method has already begun. In China, it is being used to disable a gene called PD-1 in immune cells taken from individuals with cancer. The edited cells are then injected back into each person’s body. PD-1 codes for an “off switch” on the surface of immune cells, and many cancers evolve the ability to thwart immune attacks by flipping the PD-1 switch to “off”. On the edited immune cells there is no switch for cancer cells to flip.